* Syndax Pharmaceuticals Inc SNDX.OQ reported a quarterly
adjusted loss of 98 cents per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of -73 cents. The mean expectation of
thirteen analysts for the quarter was for a loss of $1.11 per
share. Wall Street expected results to range from $-1.26 to -82
cents per share.
* Revenue was $12.50 million; analysts expected $11.20
million.
* Syndax Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 98 cents.
* The company reported a quarterly loss of $84.13 million.
* Syndax Pharmaceuticals Inc shares had fallen by 1.6% this
quarter and lost 12.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 0.4%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Syndax
Pharmaceuticals Inc is 35.00
This summary was machine generated from LSEG data November 6 at
04:44 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.11 -0.98 Beat
Jun. 30 2024 -0.91 -0.80 Beat
Mar. 31 2024 -0.98 -0.85 Beat
Dec. 31 2023 -0.99 -1.00 Missed